ICLR vs YDES Stock Comparison

Icon and YD Bio Prices as of Oct 26, 2026 Peers: Industry group
ICLR Icon Plc
$183.78 +6.6% 1M +3.2% 1Y
Market cap
$14.49B
P/E
44.1x
Revenue (TTM)
$8.33B
Div. yield
–
Contract Research Healthcare
4 wins
YDES YD Bio Ltd
$5.29 -7.7% 1M -69.2% 1Y
Market cap
$389.97M
P/E
–
Revenue (TTM)
—
Div. yield
–
Biotechnology Healthcare

Head to Head

4 decided of 12

Icon leads on 4 of the 12 questions below (Icon 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLRYDESLeader
Larger companyMarket capitalisation $14.49B $389.97M ICLR
Cheaper on earningsLower P/E, profitable companies only 44.1x — –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.9x — –
Faster revenue growthRevenue growth, trailing twelve months +3.7% — –
More profitableNet margin, trailing twelve months 3.9% — –
Better return on capitalReturn on invested capital 1.3% — –
Less leveragedLower net debt / EBITDA 3.5x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +3.2% -69.2% ICLR
Better 5-year returnAnnualised price return, 5 years -8.2%/yr -12.2%/yr ICLR
Less volatileAnnualised volatility, 1 year 73.8% 134.5% ICLR
Higher overall scoreMean of the five percentile scores vs peers 69/100 — –

Percentile Scorecard

ICLRYDES

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLRYDES
Valuation 90 #2 of 11 –
Growth 30 #8 of 11 –
Profitability 80 #3 of 11 –
Financial Health 75 #4 of 13 39 #405 of 658
Shareholder Returns – –
Overall 69 –
  • ICLR ranked among 13 companies in Pharma Services
  • YDES ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLRYDESSPY
1 month +6.6%-7.7% -0.8%
3 months +8.9%+131.0% +3.5%
6 months +78.1%-3.1% +7.0%
Year to date +0.9%-56.6% +12.2%
1 year +3.2%-69.2% +13.0%
3 years -21.9%-51.9% +86.3%
3 years, per year -7.9%-21.7% +23.1%
5 years -34.8%-47.8% +68.6%
5 years, per year -8.2%-12.2% +11.0%
10 years +125.7%— +258.0%
10 years, per year +8.5%— +13.6%

Risk

MeasureICLRYDESSPY
Volatility, 1Y 73.8%134.5% 12.7%
Downside volatility, 1Y 87.9%132.8% 12.7%
Beta vs S&P 500, 1Y 1.450.30 1.00
Return / volatility, 1Y 0.04-0.51 1.02
Max drawdown, 5Y -76.9%-91.8% -25.4%
From 52-week high -9.4%-69.1% -1.8%
52-week high $202.92$17.11 $779.14
52-week low $80.08$1.90 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLRYDES
P/E now vs peer median 43.8xmedian 36.5x —median 17.1x
P/S now vs peer median 1.7xmedian 2.7x —median 8.8x
EV/EBITDA now vs peer median 23.5xmedian 37.7x —median 17.1x
P/FCF now vs peer median 15.9xmedian 20.7x —median 18.0x
P/B now vs peer median 1.5xmedian 2.9x 83.7xmedian 2.1x
PEG now vs peer median -3.55median 2.04 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLRYDES
Revenue $8.33B –
Gross profit $2.01B –
Operating income $325.64M –
Net income $69.55M –
Free cash flow $883.82M –
EPS (diluted) $4.16 –
Cash & equivalents $928.39M $2.66M
Total debt $13.60B –
Shares (diluted) 78.97M 66.72M
Enterprise value $11.60B $377.70M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLRYDES
P/E 43.8x –
P/FCF 15.9x –
P/Operating cash flow 13.2x –
P/S 1.7x –
P/B 1.5x 83.7x
P/Tangible book 2.3x 187.2x
EV/EBITDA 23.5x –
EV/EBIT 50.8x –
EV/Revenue 2.0x –
EV/FCF 18.7x –
EV/Operating cash flow 15.5x –
PEG (3Y EPS CAGR) -3.55 –

Growth

14 metrics
MetricICLRYDES
Revenue growth (1Y) 3.7% –
Revenue CAGR (3Y) 1.8% –
Gross profit growth (1Y) -11.5% –
Gross profit CAGR (3Y) -4.7% –
Operating income growth (1Y) -66.6% –
Operating income CAGR (3Y) -28.0% –
Net income growth (1Y) -91.0% –
Net income CAGR (3Y) -48.5% –
EPS growth (1Y) -59.0% –
EPS CAGR (3Y) -12.3% –
Operating cash flow growth (1Y) -7.4% –
Operating cash flow CAGR (3Y) 26.1% –
Free cash flow growth (1Y) -10.7% –
Free cash flow CAGR (3Y) 32.4% –

Profitability

14 metrics
MetricICLRYDES
Gross margin 24.2% –
EBITDA margin 8.4% –
Operating margin 3.9% –
Pretax margin 1.6% –
Net margin 3.9% –
FCF margin 10.6% –
Operating cash flow margin 12.8% –
Return on equity 6.4% –
Return on assets 3.7% –
Return on invested capital 1.3% –
Return on capital employed 2.6% –
Asset turnover 0.5x –
Cash conversion (OCF / net income) 15.4x –
Stock comp / revenue 1.4% –

Financial Health

11 metrics
MetricICLRYDES
Debt / assets 20.7% –
Debt / equity 0.4x –
Net debt / EBITDA 3.5x –
Debt / FCF 3.8x –
Liabilities / assets 42.8% 55.5%
Equity / assets 57.2% 44.5%
Interest coverage 1.7x –
Current ratio 1.0x 5.2x
Quick ratio 0.6x 2.7x
Cash ratio 0.2x 2.5x
Altman Z-score 1.96 –

Shareholder Returns

7 metrics
MetricICLRYDES
Dividend yield – –
Net buyback yield 1.7% –
Shareholder yield 1.7% –
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLRYDES
Forward P/E 17.9xFY2026 –
EPS, next fiscal year $10.25FY2026 –
EPS growth, next FY -18.2%FY2026 –
EPS growth, the year after +22.2% –
Revenue, next fiscal year $8.52BFY2026 –
Revenue growth, next FY +3.2%FY2026 –
Revenue growth, the year after -3.2% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLRYDES
Held by institutions 100.0% –
Institutions holding 422 –
Change in shares held, QoQ +5.5% –
Institutions buying 233 –
Institutions selling 138 –
Buyers to sellers 1.69 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLRYDES
ICLR 1.00 0.10
YDES 0.10 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICLR and YDES?

Icon (ICLR) is the largest by market capitalisation: Icon (ICLR) $14.49B, YD Bio (YDES) $389.97M.

Which stock has performed better?

Over the past year Icon (ICLR) returned the most: Icon (ICLR) +3.2%, YD Bio (YDES) -69.2%. Over five years, Icon (ICLR) compounded fastest (Icon (ICLR) -8.2%/yr, YD Bio (YDES) -12.2%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Icon (ICLR) has been the steadiest (Icon (ICLR) 73.8%, YD Bio (YDES) 134.5%). Volatility measures how widely the price swings, not the risk of the business.

Do ICLR and YDES move together?

Their daily returns over the past year have a correlation of 0.10, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, ICLR and YDES?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Icon (ICLR) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.